Immunology Department, Weizmann Institute of Science, Rehovot, Israel.
J Mol Med (Berl). 2017 Oct;95(10):1021-1027. doi: 10.1007/s00109-017-1563-z. Epub 2017 Jun 27.
The last decade of research has witnessed a tremendous upsurge in our understanding of the intestinal microbiome and its role in a large range of human diseases, which has incited hopes for a rapid clinical utilization of the new insights for the development of microbiome-based therapies. Nonetheless, only a single microbiome-targeted therapy has so far found its way into clinical routine: fecal microbiota transplantation for patients suffering from recurrent Clostridium difficile infections. Herein, we discuss the current hopes, advances, challenges, and obstacles for translating basic microbiome research into therapeutic applications for a larger number of diseases and provide an outline of how such clinical applications might emerge.
过去十年的研究见证了我们对肠道微生物组及其在多种人类疾病中的作用的理解的巨大增长，这激发了人们对快速临床应用新见解以开发基于微生物组的疗法的希望。尽管如此，迄今为止，只有一种针对微生物组的疗法已经进入临床常规：粪便微生物群移植治疗复发性艰难梭菌感染患者。在此，我们讨论了将基础微生物组研究转化为治疗更多疾病的治疗应用的当前希望、进展、挑战和障碍，并概述了这些临床应用可能出现的方式。
